Asterias Biotherapeutics (AST) Tops Q2 EPS by 7c

Asterias Biotherapeutics (NYSE: AST) reported Q2 EPS of ($0.12), $0.07 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $1.53 million versus the consensus estimate of $1.14 million.

For earnings history and earnings-related data on Asterias Biotherapeutics (AST) click here.

You May Also Be Interested In

• Visa (V) stock rises as Q2 earnings, revenue come ahead of estimates
• Bank of N.T. Butterfield & Son (NTB) Tops Q1 EPS by 20c
• West Fraser Timber Co. Ltd. (WFG) Tops Q1 EPS by 17c